Court of Appeal clarifies application of 60 day time limit for hearing Anti-SLAPP motions

In its recent decision in Amorosi v. Barker, 2020 ONCA 144 (“Amorosi”), the Court of Appeal for Ontario clarified how the 60 day time...

Canadian court interprets CETA drug patent extensions more broadly than EU equivalent

The Federal Court ruled in its first case to consider the Canadian supplementary protection scheme for patented pharmaceuticals in relation to a...

Regulators push deadlines for reform implementation in response to COVID-19

As the COVID-19 pandemic saga continues to unfold, financial regulators continue to demonstrate flexibility for market participants and their staff...

Tips and awards: the OSC and SEC whistleblower programs report milestones

The enforcement team at the Ontario Securities Commission (the “OSC”) is emphasizing the unique role that industry experts should play in...

Les autorités réglementaires repoussent les délais de mise en œuvre des réformes en réponse à la COVID-19

Alors que la saga de la pandémie COVID-19 continue de se dérouler, les autorités de réglementation financière continuent de faire preuve de...

Round-up: Surveying regulatory and other relief impacting pension and benefit plans in Canada (COVID-19 update)

The COVID-19 pandemic has brought rapid regulatory and legislative responses to provide relief to Canadian businesses and workers in many areas. In...

Class action dismissed against the REM: Limits on obligations owed to public transit users

Recently, in Barré v. CDPQ Infra Inc., the Quebec Superior Court dismissed an application for authorization to institute a class action relating to...

Tour d’horizon : Revue des allègements réglementaires et autres ayant un impact sur les régimes de retraite et d’avantages sociaux au Canada (mise à jour COVID-19)

La pandémie COVID-19 a entraîné des réponses réglementaires et législatives rapides pour soutenir les entreprises et les travailleurs canadiens...

Competition Bureau reiterates its position against anti-competitive generic drug delay tactic

The Competition Bureau recently issued a press release expressing concern about the denial by one brand company, Otsuka, of samples of its kidney...